Saturday , November 28 2020

Research publishes promising results for the California research team …



Santa Clara, CA (PRNewswire / -) – Dr. Ing. The Rath Research Institute in California developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs), which are responsible for tumor growth, metastasis in tumors, and the formation of blood vessels (angiogenesis). Dr. The research team of Rath showed that the tested mice containing specific MMP-2 and MMP-9 sequences and then inoculated with peptides infected with melanoma cancer cells had an average tumor reduction of 76% compared to unvaccinated mice. Animals from the control group. Remarkably, some vaccinated animals have never developed cancer.

The study was published in the online Journal of Cellular Medicine and Natural Health in October 2018.

Cancer is still the world's second largest epidemic. The disease causes more than 7 million deaths each year. This new treatment approach has the potential to significantly change these statistics. Compared to monoclonal antibodies (Mabs) or biosimilar molecules recently developed as anti-cancer agents, the anti-MMP vaccine approach is much more effective and cost effective in the global fight against disease. While Mabs / biosensors target a specific type of cancer, the anti-MMP vaccine can combat all types of cancer. Another advantage is that, contrary to Mabs / Biosimilars, an injection should be performed once or twice a month, the anti-MMP vaccine should only be given once and several times after a few years. would be necessary.

When the anti-MMP vaccine is successfully completed, it can be offered to patients from national or international health institutions at a reasonable cost.

To make this valuable technology suitable for the majority of patients and nations around the world Rath has applied for patent protection in many countries. The institute is looking for public and government research institutions and other non-governmental organizations to develop this promising technology to successfully treat, cope with and prevent cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

BASE. Patent No. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

contact:

Dr. Alexandra Niedzwiecki
Chief Executive Officer
Dr. Rath Research Institute
E-Mail: [email protected]


Source link